(Reuters) - The company said the study showed statistical significance in the reduction of eye itching, but did not achieve statistical significance in the second main target, eye redness.
This news follows the company's announcement on Friday that U.S. health regulators rejected its treatment for eye inflammation, T-Pred. That day, ISTA lost almost a third of its market value.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment